The present invention relates to the adoptive therapy using notably CAR-T cells. Herethe inventors used a lentiviral vector approach to silence RINF […]

In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic […]

The invention relates to a bispecific antibody targeting TfR1 and a soluble antigen. The inventors demonstrate that the unique mode of interaction of […]

Pediatric liver cancers (PLC) are rare tumors. In particular, hepatoblastomas are usually treated with cisplatin-based neoadjuvant chemotherapy […]

TNF alpha blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells […]

Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cellsand evaluated Sig-1R implication in stromal cues integration by PCC […]

Pancreatic Ductal Adenocarcinoma (PDAC) still represents a therapeutic dead-end. Theinventors report that the K+ channel SK2 is stimulated by secreted […]

Inventors have shown that targeting DDR1 and DDR2 collagen receptors by Imatinib resensitizes melanoma tumors to BRAFV600E to targeted therapy and […]

Cholesterol efflux pathways have anti-inflammatory and anti-proliferative properties that could be exploited in tumor biology to unravel cancer […]

Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphomaaffects lymph nodes and extra-nodal sites with characteristic […]